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c
Purpose of review
Many international recommendations for the management of familial hypercholesterolaemia propose the
use of cascade testing using the family mutation to unambiguously identify affected relatives. In the current
economic climate DNA information is often regarded as too expensive. Here, we review the literature and
suggest strategies to improve cost-effectiveness of cascade testing.
Recent findings
Advances in next-generation sequencing have both speeded up the time taken for a genetic diagnosis and
reduced costs. Also, it is now clear that, in the majority of patients with a clinical diagnosis of familial
hypercholesterolaemia in whom no mutation can be found, the most likely cause of their elevated LDL-
cholesterol (LDL-C) is because they have inherited a greater number than average of common LDL-C raising
variants in many different genes. The major cost driver for cascade testing is not DNA testing but treatment
over the remaining lifetime of the identified relative. With potent statins now off-patent, the overall cost has
reduced considerably, and combining these three factors, a familial hypercholesterolaemia service based
around DNA-cascade testing is now less than 25% of that estimated by NICE in 2008.
Summary
Although all patients with a clinical diagnosis of familial hypercholesterolaemia need to have their LDL-C
lowered, cascade testing should be focused on those with the monogenic form and not the polygenic form.
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INTRODUCTION
Familial hypercholesterolaemia is an autosomal
dominant disorder, characterized clinically by elev-
ated LDL-cholesterol (LDL-C) levels, and as a con-
sequence premature mortality and morbidity from
coronary heart disease (CHD). There is a 50% risk of
CHD in a man with familial hypercholesterolaemia
by the age of 50 years and in a woman with familial
hypercholesterolaemia by the age of 60 years, which
has been reported in several studies, as previously
summarized [1]. Once identified, individuals with
heterozygous familial hypercholesterolaemia can be
successfullytreatedbylipid-loweringagentsparticu-
larly statins which reduce their CHD mortality to
that of the general population. Familial hypercho-
lesterolaemia affects about one of 500 [2] to one of
200 [3,4
&&] individuals of the Caucasian population,
with therefore between 120000 and 240000 people
in the UK with heterozygous familial hypercholes-
terolaemia,andanestimated1.8–4.5millionpeople
affected in Europe, of whom at least 75% are un-
diagnosed [2]. Cascade testing, using the family
mutation to identify carrier relatives unambiguously,
is a cost-effective method of finding additional fam-
ilial hypercholesterolaemia patients, and has been
used extensively in some countries in Europe,
most notably in Holland, with great success [5
&].
In 2008, the UK agency NICE published an familial
hypercholesterolaemia guideline for implementing
genetic testing of index case and cascade testing of
their relatives on the basis of compelling evidence of
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clinical efficacy and cost-effectiveness [6], and
severalothercountryspecificandinternational con-
sensus guidelines have made similar recommen-
dations [7]. Using the NICE model, it has been
estimated that DNA-based cascade testing for iden-
tifying and managing affected relatives had an
incremental cost-effectiveness ratio (ICER) of
 £3666 ( s4600) per quality adjusted life year
(QALY) gained [8], which is much more cost-
effective than many current ongoing screening pro-
grammes. However, in the UK and many countries
in Europe, DNA-based cascade testing is still not
being undertaken, in large part because of the per-
ception that the provision of the service is too
expensive in difficult economic times. Here, we
review the literature regarding the cost-effectiveness
of DNA-based cascade testing for familial hypercho-
lesterolaemia and examine how recent advances
in genetic knowledge and methods, and the cost
reductionachievedbychangingthemodelofcareand
using off-patent statins can influence overall costs.
GENETIC TESTING FOR FAMILIAL
HYPERCHOLESTEROLAEMIA
Roughly, 93% of patients with identified genetic
cause have a mutation in the receptor for LDLs
(LDLR) and the University College London world-
wide database currently holds more than 1200 pub-
lished and confirmed genetic causes of familial
hypercholesterolaemia [9]. The second most com-
mon cause of familial hypercholesterolaemia world-
wide is a single mutation in the gene for
apolipoprotein B (APOB) which prevents efficient
binding of the LDL-C particle to the receptor and
therefore reduces clearance of LDL-C from the blood
by the liver ( 5% of familial hypercholesterolaemia
patientsintheUK[10]).Theothermolecularcauseof
familial hypercholesterolaemia is that of mutations
inthegeneforproproteinconvertasesubtilisin/kexin
type 9 (PCSK9), which encodes the PCSK9 protein
which is involved in the degradation of the LDL-
receptor during its recycling and cellular trafficking.
Mutations causing familial hypercholesterolaemia
are gain-of-function, and in the UK a common
mutation in this gene explains about 2% of patients
with familial hypercholesterolaemia [10].
Since the announcement of the entire human
genome sequence in 2007 there has been huge tech-
nological advances, such that it is now possible to
use ‘next-generation sequencing’ (NGS) methods to
sequence the whole of the genome of an individual,
or more usefully, all the parts of the genome that
code for proteins, known as ‘exome sequencing’
[11,12,13
&&,14]. DNA diagnostic labs have now devel-
opedmethodswherebyalltheproteincodingregions
of the genome for the known familial hypercholes-
terolaemia genes can be captured and sequenced in
one run with high accuracy [15
&&,16
&,17
&], and with
the addition of small ‘barcoding’ sequence runs into
the primers used to PCR amplify the regions of
interest, it is now possible to mix the samples from
up to 96 individuals and analyse them in one run
with high accuracy [17
&]. This economy of scale is
helping to drive down prices so that now a full
familial hypercholesterolaemia diagnostic scan can
be completed for roughly £250 and the data can also
be used to look to see if an individual has a large
insertion or deletion of the gene, which occurs in
about 5% of patients [15
&&]. Using these methods
produces a large amount of sequence data, which
must be analysed using statistical and bioinformatics
approaches and this has increased the number of
occasionswherebyavariantofuncertainsignificance
is identified [18
&&]. This creates a diagnostic conun-
drum which clearly cannot be reported as familial
hypercholesterolaemia-causing to the clinician or
patient but which requires either in-vitro molecular
assays to examine impact on transcription or correct
splicing, or by family studies to see if other relatives
who have inherited this variant have also shown
highLDL-Clevels.SeveralnovelvariantsintheAPOB
gene have also been identified and shown to be
familial hypercholesterolaemia-causing using in-
vitro assays [19,20
&&].
POLYGENIC FAMILIAL
HYPERCHOLESTEROLAEMIA
Overall,  60% of patients with a clinical diagnosis of
possible or definite familial hypercholesterolaemia
KEY POINTS
  Recent developments in NGS methods have improved
the cost and time efficiency of genetic diagnosis for
familial hypercholesterolaemia.
  Cascade testing to identify relatives affected by familial
hypercholesterolaemia is most cost-effective in families
diagnosed with the monogenic form of
familial hypercholesterolaemia.
  The cost of cascade testing in familial
hypercholesterolaemia families has significantly fallen
mainly due to the reduction in costs of lipid-
lowering therapy.
  A ‘dual care’ approach for the familial
hypercholesterolaemia patients’ management, and
avoiding cascade testing in relatives of polygenic
hypercholesterolaemia cases, can provide further
savings on cascade testing.
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(i.e. having a Dutch Lipid Clinic Score of over 5) are
mutation negative by conventional testing, and in
this group it is now clear that the familial hyper-
cholesterolaemia phenotype can be reproduced by
an accumulation of common small-effect LDL-C
raising alleles. This was first reported in 2013
[21
&], and now (Fig. 1) confirmed in samples from
an additional six different countries and in both
adults and children [22
&&]. The data indicate that
in clinical familial hypercholesterolaemia but
mutation-negative patients, at least 80% are likely
to have a polygenic cause of the elevation in LDL-C
rather than an as yet unidentified single gene
mutation. Cascade testing would be less effective
in such cases, since the number of them inheriting
this high number of LDL-raising single nucleotide
polymorphisms (SNPs) would be considerably lower
than the 50% affected relatives expected for mono-
genic inheritance. We proposed [21
&] that patients
with a familial hypercholesterolaemia phenotype,
in whom no familial hypercholesterolaemia-
causing mutation can be found, should be given
the clinical diagnosis of polygenic hypercholester-
olaemia, and not familial hypercholesterolaemia.
This should not, however, affect the treatment of
these patients, but would influence the decision to
conduct cascade testing in their relatives [21
&].
CLINICAL UTILITY OF DNA TESTING
There are several reasons why, based on published
evidence, the NICE guidelines for familial hyper-
cholesterolaemia published in 2008, and the NICE
quality standards, published in 2013 emphasized
the clinical utility of DNA testing. The first is
because there is a significant overlap in the
distribution of LDL-C levels in mutation carriers
and their first-degree relatives who do not carry
a mutation [23,24], and this overlap reduces the
efficiency of cascade testing. The cascade testing
programmes that have been carried out so success-
fully in Holland [5
&,24] and that are now being
actively pursued in both Wales [25] and Scotland
[26], therefore use DNA testing to identify those
with a mutation and only cascade test in
mutation-positive families. Although false-positive
results based on LDL-C levels identify individuals
whose LDL-C is high and may need to be treated,
if they do not carry the family mutation, testing
their children will clearly result in no (or very low)
frequency of new familial hypercholesterolaemia
patients. The opposite of this is that in the false-
negative individuals who carry a mutation but
whose LDL-C level is a below the diagnostic
threshold, their low LDL-C may be because they
have luckily inherited LDL-C lowering genetic var-
iants or are adopting an LDL-C lowering environ-
ment, but clearly 50% of their children are at risk of
inheriting the mutation and may not be lucky
enough to take on the lifestyle or have inherited
the LDL-C-lowering variants.
COST-EFFECTIVENESS OF DIFFERENT
STRATEGIES FOR CASCADE TESTING IN
FAMILIAL HYPERCHOLESTEROLAEMIA
FAMILIES
The cost-effectiveness literature for familial hyper-
cholesterolaemia has been recently reviewed [27].
Six studies reported on the cost-effectiveness
of familial hypercholesterolaemia screening and
subsequent treatment of the identified relatives.
All such papers use published estimates of the high
risk of CHD in men and women with familial hyper-
cholesterolaemia (as summarized in [1]), and the
efficacy of the early-in-life initiated treatment, as
has been demonstrated in the UK Simon Broome
Study and in Holland [28,29]. These CHD estimates
wereexaminedindetailbyNICECG71andaccepted
as robust and used in their published analysis [8].
Compared with no screening the ICER of screening
ranged from s3177 to s29554 per life year gained.
The results were sensitive to the underlying preva-
lence of familial hypercholesterolaemia among the
population being examined, the validity of the
screening test and the price and efficacy of lipid-
lowering therapy. The authors concluded that over-
all, cascade testing for new cases of familial hyper-
cholesterolaemia was cost-effective, but there were
uncertainties in the modelling methods, especially
with regard to the use of different approaches to
assess the outcomes of treatment. It was recognized
Simon Broome (n = 321)
Belgium (n = 451)
The Netherlands (n = 572)
The Netherlands (children, n = 22)
Greece (children, n = 60)
Canada (n = 37)
Italy (n = 58)
Poland (n = 15)
Israel (n = 43)
Total
–0.5 –0.3 –0.1 0.1 0.3
Standardized mean diffference
0.5 0.7 0.9 1.1 1.3 1.5
FIGURE 1. The overall difference between the combined
mutation-negative familial hypercholesterolaemia groups
and the approximately 3000 healthy individuals from the
Whitehall II study was 0.38 ( 0.027), P<10
 15. Data from
[22
&&].
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that cost-effectiveness would improve further once
atorvastatin and rosuvastatin lost exclusivity.
These issues were examined in more detail in a
follow-up paper [30
&&] using data from an Australian
healthcare perspective. Using a Markov model and
a 10-year time horizon to simulate the onset of first-
ever CHD and death in close relatives of monogen-
etic familial hypercholesterolaemia index cases
the decision-analysis compared the clinical con-
sequences and costs of cascade testing versus no
testing. The annual risk of CHD and benefits of
treatment were estimated from a cohort study,
and the underlying prevalence of familial hyper-
cholesterolaemia, sensitivity, specificity, cost of
screening, treatment and clinic follow-up visits were
derived from a cascade screening service for familial
hypercholesterolaemia in Western Australia. The
model was cost-effective. It estimated that testing
would reduce the 10-year incidence of CHD from
50.0 to 25.0% among people with familial hyper-
cholesterolaemia. Of every 100 people tested, there
was an overall gain of approximately 25 life-years
and 29 QALY, with an ICER in Australian dollars,
$4155 (s5850) per years of life saved and $3565
(s5093) per QALYs gained.
A recent paper by Pears et al. [31
&&] examined the
cost-effectiveness of three alternative models of care
for familial hypercholesterolaemia. The first model
considered was a specialist-led model. This model
was similar to the NICE model with the exception
that a lower proportion of patients would have
annual reviews in secondary care. The second model
involved primary care taking responsibility for the
entire adult familial hypercholesterolaemia care
pathway. In this model, no patients would be
referred to a familial hypercholesterolaemia special-
ist(locallythis means a lipidologist), andallpatients
would be reviewed annually by their GP. The final
model was a ‘dual care’ model in which primary care
would manage the majority of the familial hyper-
cholesterolaemia cascade testing pathway. In this
final model, GPs would be able to refer patients to
lipidologists if they needed further advice about
management, or to genetic services, when advice
on cascade testing was needed because a genetic
mutation had not been identified.
The authors conclude that costs for all three
models were now less than 50% of the cost of the
original estimates undertaken by NICE. By using
the latest statin costs and reduced DNA testing costs,
by reducing the proportion of patients prescribed
more expensive proprietary owned rosuvastatin and
by managing more patients with familial hypercho-
lesterolaemia in primary care, providing an familial
hypercholesterolaemia service is now much more
affordable than predicted by NICE in 2008. The
reduction in costs with generic atorvastatin now avail-
able ( £368–25pa for 40mg or £45pa for 80mg) this
reduces the cost of a 10-year service by 42.5% ( £4.8–
2.8 million). Compared with the generic atorvastatin
costing estimates, the specialist-led model reduced
10-year costs by a further 27.2%, the dual care model
by a further 32.5% and the GP-led model by a further
3 5 . 8 % .T h et h r e ea l t e r n a t i v em o d e l so fc a r ew e r en o w
less than 50% of the cost of the original estimates
undertaken by NICE. If 50% of patients with familial
hypercholesterolaemia are diagnosed early in life
and then treated optimally over a 55-year period,
£94.7 million (£1.97 million per 1000 cases) can be
s a v e dt h r o u g hr e d u c e dC Ve v e n t s ,o r£ 1 . 7m i l l i o n
(s1.2 million) per year.
Pears et al. assess their models in a population of
1.95 million, estimating the dual care model to cost
£1.89 million ( s2.6 million) over 10 years. If we
extrapolate the figure to that of the entire popu-
lationofEngland(53.9millionin2013),theoriginal
NICE model will cost approximately £134.5 million
(s95.49 million) over 10 years and the dual care
model will cost approximately £67.3 million (s47.8
million). Such a programme would include the cost
of medicines, management in primary care, referral
for specialist attention and genetic testing and
assessment of family members. However, as we
now understand that the majority of those with
no detectable mutation do not have ‘monogenic’
familial hypercholesterolaemia, costs can be
reduced further if we also only cascade test from
familial hypercholesterolaemia patients with a
monogeniccauseoffamilialhypercholesterolaemia.
Basedon(31)thiswouldbeonlyapproximately45%
of those with a clinical diagnosis of familial hyper-
cholesterolaemia, and would reduce costs still fur-
ther to approximately £28.5 million ( s40 million)
as shown in Fig. 2a (see [28] and supplementary
material for detailed assumptions of this model).
The dual model of care, excluding polygenic hyper-
cholesterolaemia cascade testing, is now less than
25% ofthecost oftheoriginal 2008 estimates under-
taken by NICE. Restricting cascade testing to mono-
genic families reduces the number of cardiac events
avoided over 10 years from 2736 to 2229 (18.5%
reduction) as shown in Fig. 2b. However, relative
cost-effectiveness jumps. For instance, in year
eight onwards the cost per cardiac event avoided
is £39489 (s28037) in the original NICE model,
£18088 (s12842) in the dual model and £7155
(s5080) in the monogenic cascade testing model.
CONCLUSION
Although almost all recent guidelines for the
identification and management of familial hyper-
cholesterolaemia recognize the utility of DNA-based
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cascade testing for the identification of at-risk
relatives, few countries to date have implemented
this as a national strategy. The advent of NGS
methods and the recognition that the vast majority
of patients with a clinical diagnosis of familial
hypercholesterolaemia but with no identified
mutation have a polygenic cause of their elevated
LDL-C suggests sensible targeting strategies for cas-
cade testing. It is likely that individuals with poly-
genic familial hypercholesterolaemia will not have
so severe atherosclerosis as monogenic familial
hypercholesterolaemia, or at least will not manifest
their cardiovascular disease at such an early age,
although further research is urgently needed to
explore this. Such individuals could be easily
managed in general practice, whereas monogenic
familial hypercholesterolaemia may well require
management in expert centres because they require
multiple drug therapies in order to reduce their
LDL-C levels to acceptable target levels, or the use
of novel lipid lowering agents such as monoclonal
antibodies to PCSK9. Use of this dual care approach
also reduces overall costs of the cascade testing and
management programme, but the major factor in
the huge reduction in costs is the availability of
potent off-patent statins. As such, the cost of pro-
viding a familial hypercholesterolaemia service has
reduced by three-quarters in the past 5 years.
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FIGURE 2. Estimate over 10 years of the costs in a monogenic cascade testing familial hypercholesterolaemia service.
(a) A comparison of costs and clinical benefits (i.e. a population of 53.9 million), assume costs based on atorvastatin
off-patent, only mutation-positive patients included as index cases for cascade testing and a cost of £250 per index test and
£70 per relative test, and based on the dual care pathway in [28]. s costs estimated assuming 1 s¼£0.71. (b) A
comparison of costs per cardiac events avoided. Adapted with permission from [28].
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